Changes in tumor cells help make ovarian cancer treatment resistant
Specific genetic changes in small populations of tumor cells can help to make ovarian cancer resistant to treatment, a new study by U.S. researchers revealed.
Gynecological cancer
Gynecological cancer overview
Gynecological cancer encompasses a group of cancers affecting the female reproductive system. Approximately 100,000 people are diagnosed with gynecological cancer in the U.S. every year. Although each type of gynecological cancer is unique, with its own symptoms, risk factors, and treatment options, reaching an early diagnosis is critical for ensuring the best possible outcomes in any of them.
Read moreGynecological cancer treatment
There are several treatment approaches for gynecological cancer, which encompasses all cancers that originate in the female reproductive system. The choice of treatment will depend on the cancer type, how far it has spread, a patient’s general health status, and other factors, such as whether the patient wishes for their fertility to be preserved.
Read moreNews
Nearly half of endometrial cancer patients respond to Rina-S in trial
Nearly half of women with hard-to-treat endometrial cancer responded to the investigational therapy Rina-S (rinatabart sesutecan) in a Phase 2 clinical trial, according to new…
Corcept seeks European approval of relacorilant for ovarian cancer
Corcept Therapeutics has submitted an application to the European Medicines Agency seeking approval of relacorilant for the treatment of platinum-resistant ovarian cancer. A similar…
Prolactin-raising antipsychotics may increase gynecological cancer risk
Women prescribed antipsychotics that raise the levels of prolactin, a hormone that stimulates milk production and regulates reproductive hormones, had double the rate of…
Stenoparib may improve survival in hard-to-treat ovarian cancer: Data
The experimental therapy stenoparib (2X-121) may help extend survival in people with hard-to-treat ovarian cancer, according to new clinical trial data announced by the therapy’s…
FDA decision on relacorilant for ovarian cancer expected in July
The U.S. Food and Drug Administration (FDA) has agreed to review Corcept Therapeutics’ application seeking approval of relacorilant to treat platinum-resistant ovarian cancer. The…
